Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease

European Journal of Clinical Investigation

Volumn 43, Issue 5, 2013, Pages 510-521

  Roca, Mihai ^a,b   Verduri, Alessia ^a   Corbetta, Lorenzo ^c   Clini, Enrico ^a,d   Fabbri, Leonardo M ^a   Beghé, Bianca ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF FLORENCE   (Italy)

^d Villa Pineta Hospital   (Italy)

Author keywords

Airway inflammation; Chronic bronchitis; Chronic heart failure; Emphysema; Infections

Indexed keywords

ASTHMA; BACTERIAL INFECTION; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONCURRENT INFECTION; DEPRESSION; DISEASE EXACERBATION; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; PNEUMONIA; PNEUMOTHORAX; POLLUTANT; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SYMPTOM; VIRUS INFECTION;

ACUTE-PHASE REACTION; HOSPITALIZATION; HUMANS; INFLAMMATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY DISTRESS SYNDROME, ADULT; SEVERITY OF ILLNESS INDEX;

EID: 84876485451     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12064     Document Type: Review

References (88)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
2. García-Sanz MT, Pol-Balado C, Abellás C, Cánive-Gómez JC, Antón-Sanmartin D, González-Barcala FJ. Factors associated with hospital admission in patients reaching the emergency department with COPD exacerbation. Multidiscip Respir Med 2012;7:6.
3. Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 2012;7:653-61.
4. Ozkaya S, Findik S, Atici AG. The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease. Clinicoecon Outcomes Res 2011;3:15-8.
5. Gudmundsson G, Ulrik CS, Gislason T, Lindberg E, Brøndum E, Bakke P et al. Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis 2012;7:571-6.
6. Agustí A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2012;9:43-6.
7. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE et al. Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012;7:e37483.
8. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37-43.
9. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-61.
10. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9.
11. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009;360:2445-54.
12. Singanayagam A, Joshi PV, Mallia P, Johnston SL. Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Med 2012;10:27.
13. Mallia P, Footitt J, Sotero R, Jepson A, Contoli M, Trujillo-Torralbo MB et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in COPD. Am J Respir Crit Care Med 2012;186:1117-24.
14. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-8.
15. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71.
16. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011;183:734-42.
17. Quint JK, Donaldson GC, Goldring JJ, Baghai-Ravary R, Hurst JR, Wedzicha JA. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest 2010;137:812-22.
18. Lodovici M, Bigagli E. Oxidative stress and air pollution exposure. J Toxicol 2011;2011:487074.
19. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005;60:293-300.
20. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R et al. Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
21. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012;185:435-52.
22. Nishino T. Dyspnea: underlying mechanisms and treatment. Br J Anaesth 2011;106:463-74.
23. Kappagoda CT, Ravi K. The rapidly adapting receptors in mammalian airways and their responses to changes in extravascular fluid volume. Exp Physiol 2006;91:647-54.
24. Lee LY. Respiratory sensations evoked by activation of bronchopulmonary C-fibers. Respir Physiol Neurobiol 2009;167:26-35.
25. Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Med Clin North Am 2012;96:789-809.
26. Ott D, Murgott J, Rafalzik S, Wuchert F, Schmalenbeck B, Roth J et al. Neurons and glial cells of the rat organum vasculosum laminae terminalis directly respond to lipopolysaccharide and pyrogenic cytokines. Brain Res 2010;1363:93-106.
27. Romanovsky AA, Almeida MC, Aronoff DM, Ivanov AI, Konsman JP, Steiner AA et al. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. Front Biosci 2005;10:2193-216.
28. Takayama K, Yuhki K, Ono K, Fujino T, Hara A, Yamada T et al. Thromboxane A2 and prostaglandin F2α mediate inflammatory tachycardia. Nat Med 2005;11:562-6.
29. Nalivaiko E, Ootsuka Y, Blessing WW. Activation of 5-HT1A receptors in the medullary raphe reduces cardiovascular changes elicited by acute psychological and inflammatory stresses in rabbits. Am J Physiol Regul Integr Comp Physiol 2005;289:R596-604.
30. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-7.
31. Bazaz R, Marriott HM, Francis SE, Dockrell DH. Mechanistic links between acute respiratory tract infections and acute coronary syndromes. J Infect 2013;66:1-17.
32. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-8.
33. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34, 892 subjects. Eur Heart J 2007;28:1205-10.
34. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-12.
35. Corsonello A, Antonelli Incalzi R, Pistelli R, Pedone C, Bustacchini S, Lattanzio F. Comorbidities of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2011;17:S21-8.
36. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, [Epub ahead of print].
37. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-5.
38. Rogha M, Behravesh B, Pourmoghaddas Z. Association of gastroesophageal reflux disease symptoms with exacerbations of chronic obstructive pulmonary disease. J Gastrointestin Liver Dis 2010;19:253-6.
39. Maclay JD, McAllister DA, Rabinovich R, Haq I, Maxwell S, Hartland S et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 2012;67:606-12.
40. Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, Geyer K et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:1211-8.
41. Mǎrgulescu AD, Rimbaş RC, Florescu M, Dulgheru RE, Cintezǎ M, Vinereanu D. Cardiac adaptation in acute hypertensive pulmonary oedema. Am J Cardiol 2012;109:1472-81.
42. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006;8:706-11.
43. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010;362:217-27.
44. Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010;138:32-8.
45. Torchio R, Gulotta C, Greco-Lucchina P, Perboni A, Avonto L, Ghezzo H et al. Orthopnea and tidal expiratory flow limitation in chronic heart failure. Chest 2006;130:472-9.
46. Torchio R, Gulotta C, Greco-Lucchina P, Perboni A, Montagna L, Guglielmo M et al. Closing capacity and gas exchange in chronic heart failure. Chest 2006;129:1330-6.
47. Patel AR, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012;141:851-7.
48. Ghoorah K, De SA, Kunadian V. Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review. Cardiol Rev 2012; doi:10.1097/CRD.0b013e318279e907. [Epub ahead of print].
49. Cheng TO. Acute dyspnea on exertion is an angina equivalent. Int J Cardiol 2007;115:116.
50. Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011;66:764-8.
51. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012;39:1097-103.
52. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003;21:1012-6.
53. Rutschmann OT, Cornuz J, Poletti PA, Bridevaux PO, Hugli OW, Qanadli SD et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? Thorax 2007;62:121-5.
54. Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB et al. Pulmonary embolism in patients exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006;144:390-6.
55. Moua T, Wood K. COPD and PE: a clinical dilemma. Int J Chron Obstruct Pulmon Dis 2008;3:277-84.
56. Julian LJ, Gregorich SE, Earnest G, Eisner MD, Chen H, Blanc PD et al. Screening for depression in chronic obstructive pulmonary disease. COPD 2009;6:452-8.
57. Papaioannou AI, Bartziokas K, Tsikrika S, Karakontaki F, Kastanakis E, Banya W et al. The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur Respir J 2012; doi:10.1183/09031936.00013112. [Epub ahead of print].
58. Neuman A, Gunnbjörnsdottir M, Tunsäter A, Nyström L, Franklin KA, Norrman E et al. Dyspnea in relation to symptoms of anxiety and depression: a prospective population study. Respir Med 2006;100:1843-9.
59. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007;167:60-7.
60. Almagro P, Calbo E, Ochoa de Echagüen A, Barreiro B, Quintana S, Heredia JL et al. Mortality after hospitalization for COPD. Chest 2002;121:1441-8.
61. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 2012;83:495-502.
62. Hardin M, Silverman EK, Barr RG, Hansel NH, Schroeder JD, Make BJ et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011;12:127.
63. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:728-35.
64. Contoli M, Baraldo S, Marku B, Casolari P, Marwick JA, Turato G et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol 2010;125:830-7.
65. Barnes PJ. Similarities and differences in inflammatory mechanisms of asthma and COPD. Breathe 2011;7:229-38.
66. Undem BJ, Nassenstein C. Airway nerves and dyspnea associated with inflammatory airway disease. Respir Physiol Neurobiol 2009;167:36-44.
67. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012;106:1124-33.
68. Corrales-Medina VF, Musher DM, Shachkina S, Chrinos JA. Acute pneumonia and the cardiovascular system. Lancet 2013;381:496-505.
69. Wijesinghe M, Perrin K, Healy B, Weatherall M, Beasley R. Randomized controlled trial of high concentration oxygen in suspected community-acquired pneumonia. J R Soc Med 2012;105:208-16.
70. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung 2006;35:58-65.
71. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008;31:396-406.
72. Kapur N, Masters IB, Chang AB. Exacerbations in noncystic fibrosis bronchiectasis: clinical features and investigations. Respir Med 2009;103:1681-7.
73. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I et al. Combined pulmonary fibrosis and emphysema: a distinct under-recognised entity. Eur Respir J 2005;26:586-93.
74. Faner R, Rojas M, Macnee W, Agustí A. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:306-13.
75. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr.et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43.
76. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;180:167-75.
77. Khan N, Jadoon H, Zaman M, Subhani A, Khan AR, Ihsanullah M. Frequency and management outcome of pneumothorax patients. J Ayub Med Coll Abbottabad 2009;21:122-4.
78. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005;112:976-83.
79. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007;115:2119-27.
80. Polatli M, Cakir A, Cildag O, Bolaman AZ, Yenisey C, Yenicerioglu Y. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008;26:97-102.
81. Ozben B, Eryüksel E, Tanrikulu AM, Papila-Topal N, Celikel T, Başaran Y. Acute exacerbation impairs endothelial function in patients with chronic obstructive pulmonary disease. Turk Kardiyol Dern Ars 2010;38:1-7.
82. Liu X, Xie C. Human endothelial progenitor cells isolated from COPD patients are dysfunctional. Mol Cell Biochem 2012;363:53-63.
83. Sala E, Villena C, Balaguer C, Ríos A, Fernández-Palomeque C, Cosío BG et al. Abnormal levels of circulating endothelial progenitor cells during exacerbations of COPD. Lung 2010;188:331-8.
84. Maclay JD, McAllister DA, Johnstone S, Raftis J, McGuinnes C, Deans A et al. Increased platelet activation in patients with stable and acute exacerbations of COPD. Thorax 2011;66:769-74.
85. Polosa R, Malerba M, Cacciola RR, Morjaria JB, Maugeri C, Prosperini G et al. Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Intern Emerg Med 2011; doi:10.1007/s11739-011-0636-1. [Epub ahead of print].
86. Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlösser NJ, Wouters EF. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008;133:350-7.
87. Küpeli E, Ulubay G, Ulasli SS, Sahin T, Erayman Z, Gürsoy A. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 2010;38:76-82.
88. Beghé B, Verduri A, Roca M, Fabbri LM. Exacerbations of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J 2013, doi:10.1183/09031936.00180812.